Epilepsy Trial, Recruiting (NCT05450978)

Epilepsy Trial, Recruiting NCT05450978 Sponsor: University of Pittsburgh Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT05450978 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women with epilepsy between the ages of 18 and 45 who are either planning to become pregnant or are in the very early stages of pregnancy (early first trimester)
Women with epilepsy who are able to keep a daily medical diary
Women with epilepsy who are able to fill out questionnaires about side effects
Women with epilepsy who are currently being treated with one of these three seizure medications: lamotrigine, levetiracetam, or oxcarbazepine

Who may not be able to join:

Women with epilepsy who have a history of functional seizures (seizures that are not caused by abnormal electrical activity in the brain — confirm with trial site if unsure)
Women with epilepsy who have a history of other serious medical conditions, including kidney disease, liver disease, or a brain condition that is getting worse over time
Women with epilepsy who are not able to keep a daily diary recording their seizures and medications
Women with epilepsy who currently use, or have recently used, alcohol or drugs in a problematic way, or who take other medications that are known to interact with their current seizure medication

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Page B Pennell, MD, The University of Pittsburgh

Phone: 4126160730

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05450978

Sponsor: University of Pittsburgh

Phase: Not Applicable

Status: Recruiting

Condition: Epilepsy

Trial contact: 4126160730

More information: https://clinicaltrials.gov/study/NCT05450978

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women with epilepsy between the ages of 18 and 45 who are either planning to become pregnant or are in the very early stages of pregnancy (early first trimester)
Women with epilepsy who are able to keep a daily medical diary
Women with epilepsy who are able to fill out questionnaires about side effects
Women with epilepsy who are currently being treated with one of these three seizure medications: lamotrigine, levetiracetam, or oxcarbazepine

Who may not be able to join:

Women with epilepsy who have a history of functional seizures (seizures that are not caused by abnormal electrical activity in the brain — confirm with trial site if unsure)
Women with epilepsy who have a history of other serious medical conditions, including kidney disease, liver disease, or a brain condition that is getting worse over time
Women with epilepsy who are not able to keep a daily diary recording their seizures and medications
Women with epilepsy who currently use, or have recently used, alcohol or drugs in a problematic way, or who take other medications that are known to interact with their current seizure medication

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Pittsburgh

Registry

ClinicalTrials.gov

Start date

20 July 2022

Est. completion

1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Anti-Seizure Medication (ASM) Clearance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov